REMAP-CAP: Ivermectin Fails to Help Hospitalized COVID-19 Patients

This adaptive platform arm provides the first randomized data on ivermectin in critically ill COVID-19 patients and finds no signal of benefit on organ support or survival.

ivermectinantiparasiticantiviralCOVID-19SARS-CoV-2REMAP-CAPadaptive platform trialcritical careorgan support-free daysmortality Critical Care / ICU

Background Information

Ivermectin fails to enhance survival in hospitalized COVID-19 cases.

This study evaluates the effectiveness of ivermectin in improving outcomes for hospitalized COVID-19 patients, a subject of significant debate. Ivermectin did not significantly improve organ support-free days or survival rates in critically or noncritically ill patients with COVID-19. The lack of benefit observed in this randomized trial suggests that ivermectin is unlikely to improve outcomes in hospitalized COVID-19 patients. Enrollment was ended due to futility. Ivermectin likely does not improve outcomes for hospitalized COVID-19 patients.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Hashmi M, Haniffa R, Jayakumar D, Beane A, Lorenzi E, Berry LR, Nasir Khoso M, Ain Khan Q, Kumar A, Altaf Kidwai A, Hills TE, Annane D, Aryal D, Au C, Baillie K, Beasley R, Best-Lane J, Bonten M, Bradbury CA, Brunkhorst FM, Burrell A, Buxton M, Cecconi M, Cheng AC, Cove ME, de Jong M, Detry MA, Duffy E, Estcourt LJ, Fitzgerald M, Fowler R, Goossens H, Green C, Hays LMC, Higgins AM, Huang DT, Ichihara N, Koirala S, Lamontagne F, Lawler PR, Lewis RJ, Litton E, Mahon N, Marshall JC, McAuley DF, McGlothlin A, McGuinness S, McQuilten ZK, McVerry BJ, Mouncey PR, Morpeth S, Netea M, Orr K, Parke RL, Parker JC, Patanwala A, Peters S, Reyes LF, Rowan KM, Saito H, Saunders CT, Santos M, Seymour CW, Shankar-Hari M, Singh V, Slater M, Tambyah PA, Tong SYC, Turgeon AF, Turner AM, van de Veerdonk F, Weis S, Zarychanski R, McArthur CJ, Angus DC, Berry SM, Gordon AC, Derde LPG, Webb SA, Murthy S, Arabi Y, Nichol AD, and the Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) Investigators

Citation: Hashmi M, Haniffa R, Jayakumar D, et al. Ivermectin for Critically and Noncritically Ill Hospitalized Patients With COVID-19: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP). Critical care medicine. 2026;54(7):1546-1562. doi:10.1097/CCM.0000000000007134

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →